Cost of three models of care for drug-resistant tuberculosis patients in Nigeria.
Florence O BadaEvaezi OkpokoroNick BlokEmmanuel MeriboleSaswata DuttPatrick DakumAlash'le AbimikuAlice ZwerlingSandra V KikPublished in: BMC infectious diseases (2019)
Utilizing a decentralized ambulatory model, is a more economically viable approach for the expansion of DR-TB care in Nigeria, given that patient beds for DR-TB treatment and care are limited and costs of hospitalized treatment are considerably more expensive than ambulatory models. Scale-up of less expensive ambulatory care models should be carefully considered in particular, when treatment efficacy is demonstrated to be similar across the different models to allow for patients not requiring hospitalization to be cared for in the least expensive way.
Keyphrases
- drug resistant
- healthcare
- palliative care
- end stage renal disease
- blood pressure
- mycobacterium tuberculosis
- ejection fraction
- newly diagnosed
- quality improvement
- prognostic factors
- multidrug resistant
- emergency department
- cystic fibrosis
- hiv infected
- patient reported
- hepatitis c virus
- hiv aids
- pseudomonas aeruginosa
- smoking cessation
- replacement therapy
- pulmonary tuberculosis
- adverse drug